U.S. Markets open in 9 hrs 7 mins
  • S&P Futures

    4,217.00
    +7.25 (+0.17%)
     
  • Dow Futures

    33,347.00
    +43.00 (+0.13%)
     
  • Nasdaq Futures

    13,345.50
    +34.25 (+0.26%)
     
  • Russell 2000 Futures

    1,980.60
    +4.30 (+0.22%)
     
  • Crude Oil

    93.83
    -0.51 (-0.54%)
     
  • Gold

    1,806.80
    -0.40 (-0.02%)
     
  • Silver

    20.33
    -0.02 (-0.12%)
     
  • EUR/USD

    1.0323
    -0.0002 (-0.0206%)
     
  • 10-Yr Bond

    2.8880
    +0.1020 (+3.66%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2196
    -0.0006 (-0.0524%)
     
  • USD/JPY

    133.1460
    +0.1470 (+0.1105%)
     
  • BTC-USD

    24,014.08
    -343.95 (-1.41%)
     
  • CMC Crypto 200

    571.11
    -3.63 (-0.63%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,507.20
    +687.87 (+2.47%)
     

Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 11th Annual SVB Leerink Healthcare Conference on Wednesday, February 16, 2022 at 2:20 p.m. ET.

To access the live or archived recording of the company presentation, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffmann La Roche, TPST-1120 is also advancing through a randomized first line, global, Phase 1b/2 clinical study in combination with the standard-of-care regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@tempesttx.com

1 If approved